



King's Research Portal

DOI:

[10.1111/dar.12263](https://doi.org/10.1111/dar.12263)

Document Version

Peer reviewed version

[Link to publication record in King's Research Portal](#)

Citation for published version (APA):

Morley, K. I., Lynskey, M. T., Moran, P., Borschmann, R., & Winstock, A. R. (2015). Polysubstance use, mental health and high-risk behaviours: Results from the 2012 Global Drug Survey. *Drug and Alcohol Review*, 34(4), 427-437. <https://doi.org/10.1111/dar.12263>

Citing this paper

Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination, volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are again advised to check the publisher's website for any subsequent corrections.

General rights

Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the Research Portal

Take down policy

If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.

This is the peer reviewed version of the following article: Morley KI, Lynskey MT, Moran P, Borschmann R, Winstock AR. Polysubstance use, mental health and high-risk behaviours: Results from the 2012 Global Drug Survey. Drug Alcohol Rev. 2015 Jul;34(4):427-37, which has been published in final form at: <http://onlinelibrary.wiley.com/doi/10.1111/dar.12263/abstract>. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving.

TITLE: Polysubstance use, mental health, and high-risk behaviours: Results from the 2012 Global Drug Survey

AUTHORS: Katherine I. Morley^{a,b,c,*}, Michael T. Lynskey^a, Paul Moran^d, Rohan Borschmann^e, Adam R. Winstock^{f,g}

^a National Addictions Centre, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, United Kingdom.

^b Clinical Epidemiology, Farr Institute for Health Informatics Research at University College London, London, United Kingdom.

^c Centre for Molecular, Environmental, Genetic and Analytic Epidemiology, Melbourne School of Global and Population Health, The University of Melbourne, Melbourne, Australia.

^d Health Services and Population Research Department, Institute of Psychiatry, Psychology, & Neuroscience, King's College London, United Kingdom.

^e Centre for Adolescent Health, Murdoch Children's Research Institute, University of Melbourne, Royal Children's Hospital, Flemington Road, Parkville 3052, Victoria, Australia

^f South London and Maudsley NHS Trust/King's College London, London, United Kingdom.

^g Global Drug Survey, London, United Kingdom.

* Corresponding Author:

National Addictions Centre, Institute of Psychiatry Psychology & Neuroscience, King's College London

4 Windsor Walk, London, SE5 8BB, United Kingdom

Email: katherine.morley@kcl.ac.uk, Telephone: +44 (0)20 7848 0664

Declaration of interest: None.

ABSTRACT

Background: Polysubstance use is associated with adverse health and social outcomes, but few studies have investigated whether these associations differ between individuals engaged in different patterns of illicit drug and non-prescription medication use.

Methods: Latent Class Analysis (LCA) was used to identify patterns of drug use in the Global Drug Survey, a purposive sample collected in late 2012 and surveyed using an online questionnaire including past-year drug use, sociodemographics, mental illness, involvement in violence and sexual behaviour. The sample analyzed (N=14,869; median age 27 years; 68.5% male) included those residing in the UK (N=5,869), Australia (N=6,313), and the USA (N=2,687).

Results: LCA of cannabis, ecstasy, cocaine, stimulants, nitrous, ketamine, benzodiazepines, and opioid pain-killer use identified six classes: no polysubstance use (Class 1, 49.1%); cannabis and ecstasy (Class 2, 23.6%); all illicit drugs (Class 3, 9.4%); ecstasy and cocaine (Class 4, 8.3%); cannabis and medication (Class 5, 5.9%); all drugs (Class 6, 3.8%). Participants diagnosed with anxiety were most likely to belong to Class 5 (OR 2.66, 95% CI 2.10-3.38). Violent behaviour was most strongly associated with Class 6 membership (OR 1.9, 95% CI 1.36-2.64). Sexual risk-taking also predicted membership of this class (OR 5.79, 95% CI 4.66-7.18), and Class 4 (OR 4.41, 95% CI 3.57-5.43).

Conclusions: Five heterogeneous groups of polysubstance users were identified in this international sample covering the UK, Australia, and USA. Anxiety disorders were associated with medication and cannabis use, while high-risk behaviours predicted use of cocaine and ecstasy, or wide-ranging polysubstance use including ketamine and medications.

28 1 - INTRODUCTION

29 Polysubstance use, the use of multiple substances within a given time frame, is
30 associated with increased risk of acute toxicity including overdose, adverse psychological
31 experiences and engaging in high-risk behaviours such as violence and unprotected sex [1-3].
32 Although polysubstance use patterns are diverse [4-6], only a few studies have explored
33 whether risk behaviours and health outcomes are the same across differing polysubstance use
34 patterns. These studies have used latent class analysis (LCA), a technique for identifying
35 subgroups, to characterize drug use patterns and their association with other participant
36 attributes. LCA studies of general population samples have demonstrated that polysubstance
37 use is associated with higher levels of drug dependence [6], mental illness [5-7], and suicidal
38 thoughts and attempts [6, 8]. Polysubstance users also have a higher likelihood of poor
39 physical health [7, 9, 10], sexually transmitted infections [5], being incarcerated [5], and
40 having experienced childhood sexual, physical, or emotional abuse [6, 11].

41 However, few LCA studies have explored patterns of illicit polysubstance use in
42 detail. In many studies, individuals using drugs other than alcohol, tobacco, or cannabis were
43 combined in one group [7, 10, 12, 13], or sometimes two, with the latter group simply
44 characterised as using a greater number of drugs [8, 11, 14]. This limited capacity to
45 distinguish different types of polysubstance use is due to multiple factors, but the prevalence
46 of illicit drug use is a key driver. Small samples or representative general population
47 samples, particularly with mostly adolescent participants, will contain relatively few
48 individuals who have used multiple illicit drugs. Including alcohol and tobacco use in the
49 LCA polysubstance model, especially in these types of samples, produces a model which is
50 dominated by use of these drugs due to their comparatively high prevalence, making it
51 difficult to identify variation in illicit drug use.

LCA excluding alcohol and tobacco use and using large adult samples (>5000 participants) have identified distinct groups of polysubstance users characterised by different patterns of illicit drug use. Lynskey *et al.* [6] identified four different patterns of lifetime illicit polysubstance use in a LCA of an Australian adult twin sample. Two groups, characterised by sedative and opioid use and by high use of all substances, had approximately two-fold greater odds of major depressive disorder (MDD), suicidal ideation, and suicide attempts compared to other polysubstance groups. These two patterns of use have also been associated with MDD and generalized anxiety disorder (GAD) in large-scale studies of adults from the USA where substance use was defined using measures of abuse/dependence [15], and past-year use in those meeting criteria for alcohol dependence [5]. Additionally, these studies found an association between use of a wide range of illicit drugs and conduct disorder [6] or “deviant behaviour” (attacking others, selling illegal drugs, or stealing) [5]. These studies have demonstrated that patterns of illicit drug use are more complex than a simple increase in the number of drugs used, as are the associations between polysubstance use and mental health. However, these studies were based on data collected primarily in adults and prior to 2008; it is unclear whether the same patterns of use would be observed in more recent samples, particularly participants who use drugs that have only recently seen an increase in use, such as ketamine.

We build on this research using data from the 2012 Global Drug Survey (GDS; www.globaldrugsurvey.com) to conduct a LCA of past year illicit and prescription drug use in a large sample of teenagers and adults. This survey provides a novel perspective on polysubstance use as it has collected very large samples with higher rates of substance use than the general population, facilitating the investigation of polysubstance use involving drugs for which the population prevalence of use is relatively low. GDS conducts annual anonymous online surveys of drug and alcohol use using research tools based on work

conducted by the group over the last decade [16-24]. Using these data, we first characterised patterns of self-reported drug use as the subgroups in the GDS sample to see if they differed from previous large-scale LCA studies. We then explored associations between patterns of drug use and socio-demographic characteristics, mental health problems, and high-risk behaviours, particularly whether the direction or strength of these associations varied between polysubstance groups.

2 - METHODS

2.1 - Sample

GDS is an anonymous, annual online survey of drug use promoted in partnership with the dance music magazine Mixmag, the Guardian and Fairfax Media, and also distributed through Facebook, Twitter, social news website Reddit, and drug discussion forums. The sample is non-random and should not be seen as representative of drug users. Between 15th November 2012 and 2nd January 2013 22,289 responses were received from participants resident in 125 countries [25]. Due to the sensitive nature of the survey IP addresses were not collected, consequently multiple entries from one IP address could not be eliminated. However, it is unlikely that participants completed the survey multiple times due to the substantial time commitment required and absence of material incentives. No identical sets of responses were identified. In order to use a relatively homogeneous sample the analyses reported here were limited to residents of the United Kingdom (UK), Australia, and the United States of America (USA) who provided their sex and age. These countries were chosen because residents of these countries made up the majority (72.5%; for most countries less than 100 individuals participated), and the level of use for the illicit drugs we considered is similar across countries [26]. Further discussion of the design, utility, validity, and limitations of the GDS is available [11, 16-24]. Ethical approval was received from the Joint South London and Maudsley and Institute of Psychiatry NHS Research Ethics Committee.

102 2.2 - Measures

103 2.2.1 - Past 12 month drug use

104 LCA was used to identify of distinct patterns of self-reported illicit drug and non-
105 prescribed medication use in the previous 12 months. Respondents were asked whether they
106 had used each of an extensive list of drugs in the past 12 months; drug categories for which at
107 least 10% of participants endorsed use were included. Eight drugs were selected on this
108 basis:

- 109 • Cannabis (grass, skunk, resin, and oil)
- 110 • Ecstasy (MDMA pills and powder)
- 111 • Cocaine
- 112 • Stimulants (dexamphetamine, methylamphetamine, and mephedrone)
- 113 • Nitrous oxide
- 114 • Ketamine (also including methoxetamine and N-ethylketamine)
- 115 • Benzodiazepines (non-prescription use only)
- 116 • Opioid Painkillers (non-prescription use only)

117 2.2.2 - Predictors of class membership

118 To test whether classes identified by LCA differed on other characteristics, we
119 investigated whether class membership was associated with socio-demographic
120 characteristics, tobacco and alcohol use, mental health diagnoses, and risk behaviours.

121 Socio-demographic characteristics: Gender and country of residence were used as reported.
122 Age was collected as a continuous variable and then categorized. Sexual orientation, living

situation, and highest educational qualification were derived directly from individual questions, with some categories collapsed due to small numbers (e.g. homosexual and bisexual orientation categories were combined). Occupational status was derived from three questions on whether participants were working, studying, or unemployed, combined to categorize participants as studying only, studying and working, working only, or unemployed.

Substance use: Tobacco and alcohol use were defined as any use in the preceding 12 months. Hazardous alcohol use was assessed using the 10-item AUDIT questionnaire [27, 28]. Participants were asked whether they wanted to use less of any of illicit or non-prescribed drugs they reported using. Responses relating to drugs included in the LCA were combined to create an overall indicator of participant desire to use less of any drug.

Mental health: Participants were asked “Have you ever been diagnosed with a mental illness?” with responses combined in a single variable indicating depression, anxiety, or both (although other diagnoses could be recorded, few participants reported diagnoses other than anxiety and depression). Personality disorder was screened for using the Standardised Assessment of Personality – Abbreviated Scale (SAPAS), with a threshold of three used to indicate probable personality disorder [29, 30].

High risk behaviour: Involvement in violent incidents was indexed by self-reported participation in a fight with another adult in the last 12 months. Participants were then asked whether they had taken drugs (other than alcohol) prior to involvement in the incident. These questions were combined to create a variable indicating whether participants had been involved in a violent incident, and if so whether they had taken drugs when it occurred. Sexual risk-taking was defined as having two or more sexual partners in the past year and not using condoms on all occasions of penetrative sex (as defined in [31]). Participants were

asked to report emergency treatment due to any substances they endorsed use of; due to the low number of positive responses per drug, these were combined into a single variable indicating emergency treatment due to any illicit drug use.

2.3 - Statistical analyses

LCA identifies subgroups, or latent classes, within a sample using participant characteristics defined as categorical variables. The aim is not to represent all possible combinations of characteristics but to identify the main patterns present, assuming some measurement error [32, 33]. For this study, this translates to identifying patterns of illicit drug and medication use based on reported past-year use of these substances.

To find the likely number of subgroups, models postulating increasing numbers of latent classes were sequentially fitted, with identification of each model evaluated by refitting it using 100 sets of random starting values. Models were considered identified if at least 80% of sets converged to the same solution [32, 33]. The best-fitting model was selected by examining the Akaike Information Criterion (AIC) and Bayesian Information Criterion (BIC) for each model [34], and considering the size, distinctness, and ease of interpretation of the classes identified [33]. This was informed by the class membership probabilities, the estimated proportion of the sample belonging to each class, and the item-response probabilities for each class, which represent the likely values for the set of characteristics (i.e. probability of endorsing use of each substance), given membership of a particular class.

Multinomial logistic regression models estimated via the “one-step” approach were used to explore associations between individual covariates and subgroup membership [35, 36]. Coefficient estimates for each class were combined with the known distribution of each covariate to estimate the probability of each covariate value conditional on latent class membership. Models including adjustments for sex, age, and country of residence were then

fitted for each socio-demographic, mental health, and risk behaviour variable to examine the adjusted associations with class membership.

As this was an exploratory study without prior hypotheses regarding particular population subgroups, we did not fit grouped LCA models using, for example, sex or country of residence. All tests were two-tailed but given the number of models fitted $\alpha=0.05$ was not appropriate. A Bonferroni corrected threshold would be $P \leq 0.004$, although we interpreted P-values as measures of the strength of evidence for an association [37], rather than simply applying a threshold for statistical significance. Analyses were conducted in R (version 3.0.2 for Windows) using the LCCA package (version 1.1.0) [36].

3 - RESULTS

3.1 - Sample characteristics

From the complete sample of 22,289 participants, we excluded 6,122 not resident in the three chosen countries. A further 1,298 were excluded due to missing age and/or sex (524 missing both, 723 missing sex, 51 missing age), leaving 14,869 individuals. Most participants were male (68.5%) and aged between 15 and 35 years (71.2%; Table 1). The proportions of participants endorsing past year use of the selected drugs were: cannabis (64.0%), ecstasy (37.6%), cocaine (24.8%), stimulants (10.6%), nitrous (11.7%), ketamine (14.3%), benzodiazepines (10.5%), and opioid pain-killers (11.3%).

3.2 - Latent class analysis of illicit drug use in previous 12 months

3.2.1 - Model selection

Eight latent class models (one to eight classes) were fitted but fit statistics did not unequivocally identify a best-fitting model (**Supplementary Table 1**). This discordance is not uncommon as the AIC and BIC have different strengths, but the BIC generally selects

more parsimonious models and performs better for model selection in LCA of large samples [34]. The AIC was lowest for the eight-class model, but this model was not identified (**Supplementary Figure 1**). In contrast, the BIC was lowest for the six-class model, which was identified as 98% of models had the same log-likelihood. Examination of the item-response probabilities confirmed that the subgroups identified in the six-class model had distinct characteristics (**Figure 1** and **Supplementary Table 2**), and that no class was too small (smallest class contained 4% of the sample, approximately 621 participants). These results indicated that the six-class model was most appropriate for these data.

3.2.2 - Latent class model interpretation

The item-response probabilities (**Figure 1**) suggest the classes defined by the six-class model can be characterised as follows:

1. Non-polysubstance (49.1% of the sample): No polysubstance use - moderate probability of cannabis use only;
2. Cannabis and ecstasy (23.6%): High probabilities of cannabis and ecstasy use, moderate probability of cocaine use;
3. Illicit only (9.4%): High probabilities of using most illicit drugs, but particularly cannabis, ecstasy, and ketamine;
4. Ecstasy and cocaine (8.3%): High probabilities of ecstasy and cocaine use, moderate probability of cannabis use;
5. Cannabis and medication (5.9%): High/moderate probabilities of cannabis, benzodiazepine, and opioid pain-killer use;
6. All substances (3.8%): High/moderate probabilities of using all drugs.

There were two sets of drugs that appeared to be primarily used by the same subgroups of participants. The two groups with moderate/high probabilities of endorsing ketamine use (illicit only and all substances) also had similar probabilities of endorsing nitrous oxide use (**Supplementary Table 2**). Similarly, the two groups with moderate/high probabilities of endorsing benzodiazepine use (cannabis and medication, and all substances) also had moderate/high probabilities of endorsing opioid pain-killer use. In contrast, the use of cannabis, ecstasy, cocaine, or stimulants did not display an association with use of another drug that was consistent across subgroups.

3.3 - Latent class characteristics

Compared to the polysubstance classes, participants in the non-polysubstance class were more likely to be female, and less likely to use tobacco, desire to use drugs less, have received a diagnosis of anxiety/depression, or be involved in violence or sexual risk-taking (see **Table 2**). They were also less likely to be in the 15-25 years age group compared to the polysubstance classes, with the exception of the ecstasy and cocaine class; only 7.4% of participants in this class were age 25 or younger. There were no substantial differences in past year alcohol use or hazardous alcohol use.

Participants in the cannabis and prescription medications class were more likely to report anxiety and/or depression diagnoses than members of any other class (29% compared to estimates between 11.1% and 19%), but less likely to report risky sexual behaviour (15.4% compared to estimates of 23.7% to 39.7%). Participants most likely to report risky sexual behaviour were those in the two classes defined by moderate/high probability of use of all illicit drugs (only or with prescription medications; 39.7% and 37.4% respectively). Members of these classes were also the most likely to report involvement in violent incidents, regardless of illicit drug use.

3.4 – Associations with latent class membership

Results from multinomial logistic regression models including adjustments for sex, age, and country of residence supported the majority of the associations with latent class membership suggested by the class characteristics (see **Table 3**). Sexual orientation was only associated with membership of the ecstasy and cocaine, and cannabis and medication classes; identifying as non-heterosexual increased the odds of belonging to these classes around two-fold. Having a higher degree was associated with increased odds of belonging to all polysubstance classes except those defined by use of a broad range of illicit drugs (illicit only and all drugs). Living alone increased the odds of membership of the illicit only, ecstasy and cocaine, and all drugs classes. Past year and hazardous alcohol use were not associated with class membership, but past year tobacco use was, with the strongest association identified with the all substances class (OR 28.14, 95% CI 21.43-36.94). This class also had the strongest association with reporting a desire to use drugs less (OR 70.11, 95% CI 37.7-130.4).

The adjusted multinomial logistic regression results for mental health diagnoses showed a positive association with membership of the cannabis and medication class but only for anxiety (OR 2.66, 95% CI 2.10-3.38), with similar results for personality disorder. The results for involvement in violence differed after adjustment; a strong association was still identified with the all substances class, but violence without or with drugs was also associated with the cannabis and medications class (OR 1.82, 95% CI 1.24-2.65 and OR 33.41, 95% CI 4.34-257.04 respectively). Involvement in a violent incident with drugs was also associated with membership of the ecstasy and cocaine class. Sexual risk-taking was positively associated with membership of all polysubstance classes, but particularly those defined by ecstasy and cocaine use (OR 4.41, 95% CI 3.57-5.43), and use of all drugs (OR 5.79, 95% CI 4.66-7.18).

266 4 - DISCUSSION

267 We characterised patterns of drug use in a large international sample with high levels
268 of use, identifying five polysubstance use classes that collectively contained just over 50% of
269 the sample and had distinct patterns of use that were more nuanced than a simple increase in
270 the number of drugs used. These polysubstance classes were primarily distinguished by
271 differences in use of nitrous, ketamine, benzodiazepine, and opioid pain-killers, substances
272 that have received limited attention in LCA of general population samples. Strong
273 associations with mental health and high-risk behaviours were identified for three of the five
274 polysubstance classes: ecstasy and cocaine use, cannabis and medication use, and use of all
275 drugs.

276 The polysubstance subgroups identified in this sample, and their associations with
277 mental health and risk behaviours, replicate some findings from previous studies using large,
278 general population samples. The subgroup characterised by cannabis and prescription
279 medication use, and the association between this subgroup and mental illness that we
280 identified, has also been found in studies from Australia and the USA [5, 6, 15]. An
281 association between use of many illicit drugs and antisocial behaviour was also identified in
282 these samples, although antisocial behaviour was characterised as conduct disorder and/or
283 incarceration [5, 6]. The association between sexual risk-taking and polysubstance use has
284 been identified in many settings [38]. Within the LCA literature, Connell *et al.* [39]
285 identified a strong positive association between risky sexual behaviour by US adolescents
286 and intensity of polysubstance use (alcohol, tobacco, cannabis, cocaine and inhalant use),
287 while in adults a history of sexually transmitted infections predicted polysubstance use
288 involving cannabis and cocaine [5].

We identified two sets of drugs which participants of certain subgroups endorsed use of to a similar level - benzodiazepines and opioid pain-killers, and nitrous oxide and ketamine – raising interesting questions about how and why individuals use these drugs. Simultaneous use of benzodiazepines and opioid pain-killers to enhance drug effects for recreational purposes is well documented [40], but it is unclear whether this is also true for nitrous oxide and ketamine. Both drugs are *N*-methyl-D-aspartate (NMDA)-antagonists and have medical uses as analgesics employed during anaesthesia [41, 42], so users could be substituting one for the other, or seeking to increase the overall effect by combining them. As the potential for adverse events, such as drug overdose or respiratory depression, is increased by simultaneous use, particularly involving drugs from the same class [41, 42], further investigation of these drug combinations is needed.

4.1 - Limitations

The major limitations of this study relate to the GDS sampling strategy and the time-frame of substance use. The non-representative sampling method used precludes estimating the extent to which these results are representative of the populations of the countries included. However, this strategy permitted recruitment of a large sample with high levels of substance use, facilitating a LCA that identified patterns of use that might have been overlooked in a representative general population sample. As GDS is cross-sectional, we cannot make causal inferences about relationships between mental health, risk behaviours, and polysubstance use. Additionally, we used data on 12-month drug use, which is not necessarily the same as simultaneous use during a small time window (e.g. 24-48 hours), although Quek *et al.* [9] found that most individuals reporting use of multiple drugs within a 12-month period also reported simultaneous use of those drugs.

313 5 - CONCLUSIONS

314 There are multiple, distinct patterns of polysubstance use involving illicit drugs and
315 non-prescription use of medications that are more complex than a simple increase in the
316 number of drugs used. People engaged in these different patterns of use differ in terms of
317 both sociodemographic characteristics, and mental health and risk-taking behaviours. The
318 clinical assessment and harm reduction implications of this work are potentially significant.
319 Most health promotion and harm reduction activities focus on the acute intoxication-related
320 consequences of using single drugs, but our work confirms the need to holistically address
321 polysubstance use and drug use related activities. Longitudinal research using representative
322 samples is needed to unravel the temporal nature of these associations, and to determine
323 whether longer-term trajectories of drug use and health differ between latent classes. Further
324 characterisation of simultaneous use of multiple drugs is also warranted, particularly relating
325 to frequency of use, motivations for use, and possibilities for harm reduction.

326

ACKNOWLEDGEMENTS

Role of Funding Source: Global Drug Survey is self-funded. Neither Global Drug Survey's media partners nor other funders had any role in the design, interpretation or writing of this paper. **Contributors:** ARW designed and implemented the Global Drug Survey.

MTL and ARW had the original idea for the manuscript. KIM conducted the analyses and wrote the manuscript. All authors provide input into interpreting results, critically revised the manuscript for important intellectual content, and approved the final manuscript. **Conflict of Interest:** ARW is the founder and managing director of Global Drug Survey.

Acknowledgements: We would like to thank everyone who completed the online survey for volunteering their time and expertise, our media partners Mixmag, the Guardian and Fairfax Media for their ongoing support, and Stuart Newman and Danielle Hickie for survey design and development.

REFERENCES

1. KANDEL D. B., HUANG F. Y., DAVIES M. Comorbidity between patterns of substance use dependence and psychiatric syndromes, *Drug and Alcohol Dependence* 2001: 64: 233-241.
2. MIDANIK L. T., TAM T. W., WEISNER C. Concurrent and simultaneous drug and alcohol use: results of the 2000 National Alcohol Survey, *Drug and Alcohol Dependence* 2007: 90: 72-80.
3. SCHULDEN J. D., THOMAS Y. F., COMPTON W. M. Substance abuse in the United States: findings from recent epidemiologic studies, *Current Psychiatry Reports* 2009: 11: 353-359.
4. BLOW F. C., WALTON M. A., BARRY K. L., MURRAY R. L., CUNNINGHAM R. M., MASSEY L. S. et al. Alcohol and drug use among patients presenting to an inner-city emergency department: a latent class analysis, *Addictive Behaviors* 2011: 36: 793-800.
5. HEDDEN S. L., MARTINS S. S., MALCOLM R. J., FLOYD L., CAVANAUGH C. E., LATIMER W. W. Patterns of illegal drug use among an adult alcohol dependent population: results from the National Survey on Drug Use and Health, *Drug and Alcohol Dependence* 2010: 106: 119-125.
6. LYNKEY M. T., AGRAWAL A., BUCHOLZ K. K., NELSON E. C., MADDEN P. A. F., TODOROV A. A. et al. Subtypes of illicit drug users: a latent class analysis of data from an Australian twin sample, *Twin Research and Human Genetics* 2006: 9: 523-530.
7. CONWAY K. P., VULLO G. C., NICTER B., WANG J., COMPTON W. M., IANNOTTI R. J. et al. Prevalence and patterns of polysubstance use in a nationally representative sample of 10th graders in the United States, *The Journal of Adolescent Health* 2013: 52: 716-723.
8. SMITH G. W., FARRELL M., BUNTING B. P., HOUSTON J. E., SHEVLIN M. Patterns of polydrug use in Great Britain: findings from a national household population survey, *Drug and Alcohol Dependence* 2011: 113: 222-228.
9. QUEK L.-H., CHAN G. C. K., WHITE A., CONNOR J. P., BAKER P. J., SAUNDERS J. B. et al. Concurrent and Simultaneous Polydrug Use: Latent Class Analysis of an Australian Nationally Representative Sample of Young Adults, *Frontiers in Public Health* 2013: 1: 1-9.
10. WHITE A., CHAN G. C. K., QUEK L.-H., CONNOR J. P., SAUNDERS J. B., BAKER P. et al. The topography of multiple drug use among adolescent Australians: findings from the National Drug Strategy Household Survey, *Addictive Behaviors* 2013: 38: 2068-2073.
11. ARMOUR C., SHORTER G. W., ELHAI J. D., ELKLIT A., CHRISTOFFERSEN M. N. Polydrug use typologies and childhood maltreatment in a nationally representative survey of danish young adults, *Journal of Studies on Alcohol and Drugs* 2014: 75: 170-178.
12. CARTER J. L., STRANG J., FRISIA S., HAYES R. D., HATCH S. L., HOTOPF M. Comparisons of polydrug use at national and inner city levels in England: associations with demographic and socioeconomic factors, *Annals of Epidemiology* 2013: 23: 636-645.
13. WHITESSELL N. R., BEALS J., MITCHELL C. M., NOVINS D. K., SPICER P., MANSON S. M. Latent class analysis of substance use: comparison of two American Indian reservation populations and a national sample, *Journal of Studies on Alcohol* 2006: 67: 32-43.
14. CRANFORD J. A., MCCABE S. E., BOYD C. J. Adolescents' nonmedical use and excessive medical use of prescription medications and the identification of substance use subgroups, *Addictive Behaviors* 2013: 38: 2768-2771.
15. AGRAWAL A., LYNKEY M. T., MADDEN P. A. F., BUCHOLZ K. K., HEATH A. C. A latent class analysis of illicit drug abuse/dependence: results from the National Epidemiological Survey on Alcohol and Related Conditions, *Addiction* 2007: 102: 94-104.
16. WINSTOCK A. R., WOLFF K., RAMSEY J. 4-MTA: a new synthetic drug on the dance scene, *Drug and Alcohol Dependence* 2002: 67: 111-115.
17. MCCAMBRIDGE J., WINSTOCK A., HUNT N., MITCHESON L. 5-Year trends in use of hallucinogens and other adjunct drugs among UK dance drug users, *European Addiction Research* 2007: 13: 57-64.

18. WINSTOCK A. R., BARRATT M. J. Synthetic cannabis: a comparison of patterns of use and effect profile with natural cannabis in a large global sample, *Drug and Alcohol Dependence* 2013: 131: 106-111.
19. WINSTOCK A. R., BARRATT M. J. The 12 month prevalence and nature of adverse experiences resulting in emergency medical presentations associated with the use of synthetic cannabinoid products, *Human Psychopharmacology* 2013: 390-393.
20. WINSTOCK A. R., GRIFFITHS P., STEWART D. Drugs and the dance music scene: a survey of current drug use patterns among a sample of dance music enthusiasts in the UK, *Drug and Alcohol Dependence* 2001: 64: 9-17.
21. WINSTOCK A. R., MITCHESON L., GILLATT D. A., COTTRELL A. M. The prevalence and natural history of urinary symptoms among recreational ketamine users, *BJU International* 2012: 110: 1762-1766.
22. BARRATT M. J., FERRIS J. A., WINSTOCK A. R. Use of Silk Road, the online drug marketplace, in the United Kingdom, Australia and the United States, *Addiction* 2014: 109: 774-783.
23. WINSTOCK A. R., BORSCHMANN R., BELL J. The non-medical use of tramadol in the UK: findings from a large community sample, *International Journal of Clinical Practice* 2014.
24. WINSTOCK A. R., KAAR S., BORSCHMANN R. Dimethyltryptamine (DMT): prevalence, user characteristics and abuse liability in a large global sample, *Journal of Psychopharmacology* 2014: 28: 49-54.
25. BARRATT M. J., FERRIS J. A., WINSTOCK A. R. Use of Silk Road, the online drug marketplace, in the United Kingdom, Australia and the United States, *Addiction* 2013: 774-783.
26. UNITED NATIONS OFFICE ON DRUGS AND CRIME. World Drug Report 2012, Vienna: United Nations publication; 2012.
27. SAUNDERS J. B., AASLAND O. G., AMUNDSEN A., GRANT M. Alcohol consumption and related problems among primary health care patients: WHO collaborative project on early detection of persons with harmful alcohol consumption--I, *Addiction* 1993: 88: 349-362.
28. SAUNDERS J. B., AASLAND O. G., BABOR T. F., DE LA FUENTE J. R., GRANT M. Development of the Alcohol Use Disorders Identification Test (AUDIT): WHO Collaborative Project on Early Detection of Persons with Harmful Alcohol Consumption--II, *Addiction* 1993: 88: 791-804.
29. HESSE M., MORAN P. Screening for personality disorder with the Standardised Assessment of Personality: Abbreviated Scale (SAPAS): further evidence of concurrent validity, *BMC Psychiatry* 2010: 10: 10-10.
30. MORAN P., LEESE M., LEE T., WALTERS P., THORNICROFT G., MANN A. et al. Standardised Assessment of Personality – Abbreviated Scale (SAPAS): preliminary validation of a brief screen for personality disorder Standardised Assessment of Personality, *The British Journal of Psychiatry* 2003: 183: 228-232.
31. MITCHESON L., MCCAMBRIDGE J., BYRNE A., HUNT N., WINSTOCK A. Sexual health risk among dance drug users: cross-sectional comparisons with nationally representative data, *The International Journal on Drug Policy* 2008: 19: 304-310.
32. LANZA S. T., COFFMAN D. L., XU S. Causal Inference in Latent Class Analysis, *Structural Equation Modeling* 2013: 20: 361-383.
33. LANZA S. T., RHOADES B. L. Latent class analysis: An alternative perspective on subgroup analysis in prevention and treatment, *Prevention Science* 2013: 14: 157-168.
34. NYLUND K. L., ASPAROUHOV T., MUTHÉN B. O. Deciding on the Number of Classes in Latent Class Analysis and Growth Mixture Modeling: A Monte Carlo Simulation Study, *Structural Equation Modeling* 2007: 14: 535-569.
35. FEINGOLD A., TIBERIO S. S., CAPALDI D. M. New Approaches for Examining Associations With Latent Categorical Variables: Applications to Substance Abuse and Aggression, *Psychology of Addictive Behaviors* 2013: 28: 257-267.

36. SCHAFFER J. L., KANG J. LCCA package for R users' guide (Version 1.1.0), University Park: The Methodology Center, PennState; 2013.
37. STERNE J. A., DAVEY SMITH G. Sifting the evidence-what's wrong with significance tests?, *BMJ* 2001; 322: 226-231.
38. CONNOR J. P., GULLO M. J., WHITE A., KELLY A. B. Polysubstance use: diagnostic challenges, patterns of use and health, *Current Opinion in Psychiatry* 2014; 27: 269-275.
39. CONNELL C. M., GILREATH T. D., HANSEN N. B. A multiprocess latent class analysis of the co-occurrence of substance use and sexual risk behavior among adolescents, *Journal of Studies on Alcohol and Drugs* 2009; 70: 943-951.
40. JONES J. D., MOGALI S., COMER S. D. Polydrug abuse: a review of opioid and benzodiazepine combination use, *Drug and Alcohol Dependence* 2012; 125: 8-18.
41. SAVAGE S., MA D. The neurotoxicity of nitrous oxide: the facts and "putative" mechanisms, *Brain Sciences* 2014; 4: 73-90.
42. WOLFF K., WINSTOCK A. R. Ketamine : from medicine to misuse, *CNS Drugs* 2006; 20: 199-218.

TABLES

Table 1: Demographic characteristics, mental health, and risk behaviours for the sample of 14,869 participants. Note that the “Missing” category is only shown for variables with missing data.

Variable	Values	Number	Percentage
Sex	Female	4685	31.5
Age	15 - 25 years	6521	43.9
	>25 - 35 years	4052	27.3
	>35 - 45 years	2143	14.4
	>45 years	2153	14.5
	Missing		
Country of residence	UK	5869	39.5
	Australia	6313	42.5
	USA	2687	18.1
Sexual orientation	Heterosexual	12006	80.7
	Bi/Homosexual	2508	16.9
	Missing	355	2.4
Qualifications	Higher degree	3038	20.4
	Degree	4905	33.0
	Trade/Diploma	1577	10.6
	Senior high school	3471	23.3
	Junior high school or less	1651	11.1
	Missing	227	1.5
Occupational status	Working only	6784	45.6
	Studying and working	3280	22.1
	Studying only	2880	19.4
	Unemployed	1356	9.1
	Missing	569	3.8
Living status	Partner	5353	36.0
	Shared housing	3841	25.8
	Family members	3345	22.5
	Alone	2024	13.6
	Missing	306	2.1
Tobacco use (last 12 months)	Yes	7613	51.2
Alcohol use (last 12 months)	Yes	13809	92.9
AUDIT score	Hazardous	1975	13.3
Desire to use drugs less	Yes	2601	17.5
Treatment for anxiety and/or depression	No	11386	76.6
	Anxiety	284	1.9
	Depression	1283	8.6
	Both	1443	9.7
	Missing	473	3.2
Personality disorder (SAPAS)	No	6423	43.2
	Yes	7915	53.2
	Missing	531	3.6

Variable	Values	Number	Percentage
Involvement in violent incident	No	13776	92.6
	Yes, no drugs	836	5.6
	Yes, with drugs	174	1.2
	Missing	83	0.6
Sexual risk-taking	No	10767	72.4
	Yes	2609	17.5
	Missing	1493	10.0
Emergency treatment	Yes	73	0.5

Table 2: Characteristics of Global Drug Survey 2012 participants by polysubstance use class.

Variable	Category	Non-polysubstance	Cannabis and ecstasy	Illicit only	Ecstasy and cocaine	Cannabis and medication	All drugs
Sex	Female	46.4	16.8	18.3	32.5	28.4	27.9
Age	15 - 25 years	30.9	74.4	62.6	7.4	54.2	49.3
	>25 - 35 years	33.5	12.4	18.2	45.0	22.3	24.6
	>35 - 45 years	17.7	6.6	9.6	23.8	11.8	13.0
	>45 years	17.8	6.6	9.7	23.9	11.8	13.1
Country of residence	Australia	38.6	42.3	69.5	48.6	23.3	43.6
	USA	19.3	18.1	9.6	16.1	24.1	17.7
	UK	42.1	39.6	20.9	35.2	52.6	38.7
Sexual orientation	Heterosexual	83.9	86.9	87.9	71.0	75.1	72.9
Qualifications	Higher Degree	15.1	25.4	19.6	14.1	24.0	20.5
	Degree	51.6	18.5	37.3	54.9	23.1	34.2
	Trade/Diploma	7.8	13.2	10.2	7.3	12.4	10.7
	Senior high school	17.3	29.0	22.3	16.1	27.4	23.4
	Junior high school or less	8.2	13.8	10.6	7.6	13.0	11.2
Occupational status	Working only	51.7	37.4	51.5	76.0	36.1	48.3
	Studying and working	21.1	27.3	21.2	10.5	27.9	22.6
	Studying only	18.5	24.0	18.6	9.2	24.5	19.8
	Unemployed	8.7	11.3	8.8	4.3	11.5	9.3
Living status	Partner	38.7	31.5	37.4	44.1	29.7	40.8
	Shared housing	25.6	28.6	26.1	23.3	29.3	24.7
	Family members	22.3	24.9	22.7	20.3	25.5	21.5
	Alone	13.5	15.1	13.8	12.3	15.4	13.0
Tobacco use	Yes	18.5	69.7	86.3	45.3	75.0	84.5
Alcohol use	Yes	93.3	92.7	92.5	91.0	93.6	92.6
AUDIT score	Hazardous	13.5	13.2	14.6	10.8	15.6	9.1
Desire to use drugs less	Yes	2.0	24.5	37.0	28.3	21.2	52.6
Diagnosed with anxiety and/or depression	No	79.4	88.9	87.3	84.8	61.0	79.1
	Anxiety	1.9	1.0	1.2	1.4	3.7	2.0
	Depression	8.8	4.7	5.4	6.5	16.6	8.9
	Both	9.9	5.3	6.1	7.3	18.7	10.0
Personality disorder	Yes	56.3	53.5	50.9	42.9	67.1	63.8
Violent incident	No	96.0	90.5	87.9	93.6	90.6	89.0
	Yes, no drugs	3.3	7.9	10.0	5.3	7.8	9.1
	Yes, with drugs	0.7	1.6	2.1	1.1	1.6	1.9
Sexual risk-taking	Yes	8.9	23.7	39.7	32.8	15.4	37.4
Emergency treatment	Yes	0.5	0.4	0.5	0.8	0.4	0.2


Table 3: Associations between latent class membership and participant characteristics, adjusted for sex, age, and country of residence. N indicates the number of participants included in the analysis (due to missing data for covariate). All results indicate a comparison with latent class 1 (Non-polysubstance).

Variable	Category	Cannabis and ecstasy			Illicit only			Ecstasy and cocaine			Cannabis and medication			All drugs			N
		OR	CI	P	OR	CI	P	OR	CI	P	OR	CI	P	OR	CI	P	
Sexual orientation	Heterosexual	1			1			1			1			1			1451
	Bi/Homosexual	1.05	(0.87 - 1.26)	0.64	0.81	(0.65 - 1.01)	0.06	1.74	(1.45 - 2.09)	<0.0001	2.08	(1.65 - 2.62)	<0.0001	0.92	(0.71 - 1.2)	0.54	
Qualifications	Higher Degree	2.31	(1.94 - 2.75)	<0.0001	1.09	(0.88 - 1.33)	0.43	1.58	(1.28 - 1.94)	<0.0001	2.29	(1.81 - 2.89)	<0.0001	1.01	(0.77 - 1.32)	0.96	1464
	Degree	1			1			1			1			1			
Occupational status	Trade/Diploma	0.93	(0.79 - 1.09)	0.38	0.84	(0.67 - 1.05)	0.13	1.13	(0.93 - 1.37)	0.21	1.14	(0.88 - 1.46)	0.31	0.73	(0.56 - 0.95)	0.02	
	Senior high school	0.65	(0.56 - 0.77)	<0.0001	0.55	(0.46 - 0.67)	<0.0001	0.74	(0.61 - 0.89)	0.002	0.6	(0.47 - 0.77)	0.0001	0.43	(0.35 - 0.54)	<0.0001	
	Junior high school or less	1.27	(1.07 - 1.51)	0.005	0.91	(0.71 - 1.17)	0.46	1.26	(1.04 - 1.54)	0.02	1.28	(0.96 - 1.7)	0.09	1.18	(0.92 - 1.5)	0.20	
	Working only	1			1			1			1			1			1430
	Studying and working	1.38	(1.12 - 1.69)	0.0021	0.91	(0.7 - 1.18)	0.47	0.54	(0.44 - 0.66)	<0.0001	2.11	(1.63 - 2.74)	<0.0001	1.07	(0.81 - 1.42)	0.64	
Living status	Studying only	0.9	(0.74 - 1.09)	0.28	1.06	(0.84 - 1.34)	0.63	1.9	(1.44 - 2.51)	<0.0001	1.19	(0.93 - 1.52)	0.16	1.58	(1.18 - 2.12)	0.002	
	Unemployed	1.16	(1 - 1.36)	0.05	1.02	(0.86 - 1.21)	0.83	1.97	(1.44 - 2.72)	<0.0001	1.4	(1.14 - 1.7)	0.001	1.47	(1.13 - 1.9)	0.004	
	Partner	1			1			1			1			1			1456
	Shared housing	1.27	(1.1 - 1.46)	0.001	1	(0.8 - 1.25)	0.98	0.96	(0.82 - 1.12)	0.58	1.3	(1.03 - 1.64)	0.03	0.98	(0.75 - 1.28)	0.86	
	Family members	0.72	(0.61 - 0.86)	0.0002	0.59	(0.48 - 0.72)	<0.0001	0.71	(0.58 - 0.87)	0.001	0.73	(0.57 - 0.94)	0.01	0.33	(0.26 - 0.43)	<0.0001	
Tobacco use	Alone	1.05	(0.91 - 1.21)	0.50	1.73	(1.49 - 2)	<0.0001	2.2	(1.74 - 2.79)	<0.0001	1.04	(0.85 - 1.26)	0.71	1.98	(1.66 - 2.35)	<0.0001	
	No	1			1			1			1			1			1486
	Yes	6.23	(5.12 - 7.58)	<0.0001	11.49	(9.15 - 14.42)	<0.0001	5.73	(4.8 - 6.85)	<0.0001	18.02	(13.72 - 23.66)	<0.0001	28.14	(21.43 - 36.94)	<0.0001	
Alcohol use	No	1			1			1			1			1			1486
	Yes	1.05	(0.79 - 1.38)	0.75	0.75	(0.57 - 1)	0.05	0.83	(0.64 - 1.08)	0.17	0.95	(0.64 - 1.4)	0.79	0.93	(0.66 - 1.3)	0.68	
AUDIT score	Non-hazardous	1			1			1			1			1			1486
	Hazardous	1.03	(0.83 - 1.29)	0.77	1.12	(0.89 - 1.41)	0.35	0.81	(0.65 - 1)	0.06	1.18	(0.88 - 1.57)	0.27	0.66	(0.42 - 1.02)	0.06	

Variable	Category	Cannabis and ecstasy			Illicit only			Ecstasy and cocaine			Cannabis and medication			All drugs			N
		OR	CI	P	OR	CI	P	OR	CI	P	OR	CI	P	OR	CI	P	
Desire to use drugs less	No	1			1			1			1			1			1486
	Yes	13.0	(7.0 - 24.21)	<0.0001	26.37	(14.0 - 49.63)	<0.0001	29.34	(16.2 - 53.13)	<0.0001	26.77	(14.13 - 50.72)	<0.0001	70.11	(37.7 - 130.4)	<0.0001	
Diagnosed with anxiety and/or depression	No	1			1			1			1			1			1439
	Anxiety	0.72	(0.56 - 0.92)	0.01	0.57	(0.41 - 0.8)	0.001	0.71	(0.55 - 0.9)	0.0055	2.66	(2.1 - 3.38)	<0.0001	0.97	(0.72 - 1.31)	0.85	
	Depression	1.09	(0.78 - 1.53)	0.62	1.19	(0.72 - 1.96)	0.50	1.24	(0.86 - 1.79)	0.26	0.92	(0.64 - 1.32)	0.63	0.65	(0.44 - 0.94)	0.02	
	Both	0.81	(0.53 - 1.22)	0.31	0.5	(0.27 - 0.94)	0.03	0.55	(0.34 - 0.87)	0.01	0.95	(0.6 - 1.5)	0.81	1.12	(0.71 - 1.78)	0.62	
Personality disorder	No	1			1			1			1			1			1433
	Yes	1.01	(0.87 - 1.17)	0.90	0.74	(0.63 - 0.87)	0.0002	0.74	(0.64 - 0.85)	<0.0001	1.37	(1.12 - 1.69)	0.0026	0.84	(0.7 - 1)	0.05	
Violent incident	No	1			1			1			1			1			1478
	Yes, no drugs	1.05	(0.75 - 1.47)	0.77	1.6	(1.16 - 2.19)	0.0037	1.44	(0.97 - 2.12)	0.07	1.82	(1.24 - 2.65)	0.002	1.9	(1.36 - 2.64)	0.0001	
	Yes, with drugs	6.57	(0.68 - 63.2)	0.10	2.75	(0.22 - 34.05)	0.43	26.33	(3.89 - 178.1)	0.0008	33.41	(4.3 - 257.0)	0.0007	22.07	(2.8 - 172.8)	0.0032	
Sexual risk-taking	No	1			1			1			1			1			1337
	Yes	1.48	(1.19 - 1.83)	0.0004	3.21	(2.55 - 4.03)	<0.0001	4.41	(3.57 - 5.43)	<0.0001	2.23	(1.7 - 2.93)	<0.0001	5.79	(4.66 - 7.18)	<0.0001	
Emergency treatment	No	1			1			1			1			1			1486
	Yes	1.15	(0.45 - 2.93)	0.77	0.71	(0.19 - 2.75)	0.62	1.36	(0.59 - 3.15)	0.47	0.29	(0.04 - 2.31)	0.24	1.41	(0.48 - 4.18)	0.53	

FIGURES

Figure 1: Item response probabilities (for positive endorsement of use in the last 12 months) with standard errors by latent class for the six-class model. The classes are labelled as follows: Class 1 indicates non-polysubstance; Class 2 cannabis and ecstasy; Class 3 illicit drugs only; Class 4 ecstasy and cocaine; Class 5 cannabis and medication; Class 6 indicates all drugs. Classes are shown in decreasing order of class membership probability, as per **Supplementary Table 2**.




SUPPLEMENTARY TABLES AND FIGURES

Supplementary Table 1: Model fitting statistics for the ten models postulating different numbers of latent classes. BIC indicates Bayesian information criterion; AIC indicates Akaike information criterion. Best-fitting models according to each indicator are shown in bold.

Classes	Log-likelihood	BIC	AIC
1	-54519.6	109116.0	109055.1
2	-48614.3	97391.8	97262.5
3	-48080.9	96411.6	96213.9
4	-47697.8	95731.9	95465.6
5	-47629.3	95681.2	95346.5
6	-47538.8	95586.8	95183.7
7	-47514.4	95624.5	95152.9
8	-47499.4	95680.9	95140.8

Supplementary Figure 1: Results of model identification evaluation. Each panel displays the results for a model with the specified number of classes. Log-likelihood values are graphed for 100 models fitted from different starting values for each latent class model. The red horizontal line indicates the threshold of 80%.



Supplementary Table 2: Estimates and standard errors for class membership probabilities and item response probabilities (probability of endorsing substance use) from six-class latent class model for illicit and prescription drug use in the previous 12 months.

Probability	Drug	Non-polysubstance		Cannabis and ecstasy		Illicit only		Ecstasy and cocaine		Cannabis and medication		All drugs	
		Estimate	S.E.	Estimate	S.E.	Estimate	S.E.	Estimate	S.E.	Estimate	S.E.	Estimate	S.E.
Class membership		0.49	0.01	0.24	0.02	0.10	0.01	0.08	0.02	0.06	0.01	0.04	0.01
Item response	Cannabis	0.42	0.01	0.93	0.03	0.92	0.02	0.60	0.06	0.83	0.02	0.95	0.01
	Ecstasy	0.01	0.01	0.63	0.04	0.99	0.01	0.82	0.04	0.38	0.05	0.96	0.02
	Cocaine	0.03	0.00	0.28	0.03	0.64	0.02	0.75	0.06	0.26	0.03	0.78	0.03
	Stimulants	0.01	0.00	0.09	0.01	0.32	0.02	0.23	0.03	0.21	0.02	0.51	0.04
	Nitrous	0.01	0.00	0.12	0.01	0.53	0.03	0.05	0.02	0.17	0.02	0.48	0.03
	Ketamine	0.03	0.00	0.07	0.01	0.72	0.04	0.19	0.04	0.08	0.02	0.58	0.04
	Benzodiazepines	0.02	0.00	0.03	0.01	0.20	0.03	0.11	0.02	0.61	0.06	0.69	0.05
	Opioid Painkiller	0.05	0.00	0.06	0.01	0.04	0.03	0.04	0.02	0.61	0.06	0.76	0.09